In the high-stakes world of small and mid-sized pharmaceutical companies, a single drug can make or break a company’s market valuation. Unlike established, large-cap pharmaceutical giants with diverse portfolios, these smaller biotech firms often have a limited number of drug candidates in the pipeline.